HC Wainwright & Co. Reiterates Neutral on Biohaven, Maintains $10 Price Target
HC Wainwright & Co. analyst Douglas Tsao reiterates Biohaven (NYSE:BHVN) with a Neutral and maintains $10 price target.
Stocks · News reference
Biohaven Discloses That FDA Demanded Pause In BHV7000-303 Enrolment; Dosing Continues And Topline Data Readout Remains On Timeline For H2 2026
In June 2026, we announced that enrollment in BHV7000-303 was complete. Dosing continues and topline data readout remains on timeline for the second half of 2026. As part of the nonclinical characterization of certain
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
FDA Pauses New Enrollment for Biohaven Epilepsy Drug Program
Biohaven reports an FDA partial clinical hold on BHV-7000 new enrollment while keeping pivotal epilepsy trial data readouts on track.
Biohaven shares are trading lower after the company announced the FDA ordered a pause on new enrollment in BHV-7000 program and issued a partial clinical hold on September 4, pending additional nonclinical metabolite data.